Since CTNNB1 mutation has been proved to be related to tumor recurrence, the prediction of CTNNB1 mutation in craniopharyngioma can facilitate surgical treatment and reduce postoperative recurrence rates with molecular targeted drugs. This evidence concerns the gene CTNNB1 and craniopharyngioma.